Pancreatic cancer is the fourth most common cause of cancer death in the United States, with over 34,000 patients expected to die from the disease this year. 1 At the time of diagnosis, most patients with pancreatic carcinoma have advanced disease either locally or with metastases. 2 Many of these patients have local complications, including pain and biliary or intestinal obstruction, and their median life expectancy is only 6 to 10 months. 2 Patients with locally advanced disease have traditionally been treated with systemic 5-fluorouracil (5-FU) and radiation, although more recently gemcitabine, alone or with erlotinib, has also become a standard of care for locally advanced pancreatic cancer (LAPC). [3] [4] [5] Recent data suggest that patients who achieve disease stabilization with induction chemotherapy benefit from consolidation chemoradiation therapy (CRT). 6 Despite these modest advances, life expectancy remains, however, short, and morbidity is high. 7 More effective modalities of treatment for LAPC are clearly needed.
Local treatment may ameliorate symptoms and improve outcome in patients with locally predominant pancreatic cancer. Direct intratumoral delivery has the theoretic potential to deliver high local concentrations of a therapeutic agent while minimizing systemic side effects. CT-or abdominal USguided percutaneous intratumoral injection is feasible but may be limited by the inability to assess the entire extent of a pancreatic tumor. 8 The efficacy, tolerability, and safety of repeated EUS-guided fine-needle viral injection (EUS-FNI) of pancreatic tumors, especially when performed transgastrically, has been shown previously. 9 Tumor necrosis factor-␣ (TNF-␣) has potent antitumor effects through its effect on tumor vasculature and a direct cytotoxic effect. [10] [11] [12] [13] TNF-␣ may also function as a radiosensitizer by increasing the levels of hydroxyl radicals or other radical products, thereby enhancing the oxidative damage produced by radiation. 14, 15 Clinical studies with TNF-␣, however, have been limited by severe systemic toxicity. 15, 16 TNFerade Biologic (AdGVEGR.TNF.11D) is a novel means of selective delivery of TNF-␣ to tumor cells that uses gene transfer. 17 TNFerade Biologic consists of a portion of the radiation-inducible Egr-1 promoter gene upstream to a TNF-␣ cDNA and incorporates this into an E1, E4, partial E3-, replication-deficient adenovirus type 5, providing spatial and temporal control of the radiosensitivity and cytotoxicity provided by TNF-␣. 17 Preclinical xenograft studies have demonstrated the potent anticancer properties of locally administered TNF-␣ gene therapy with minimal systemic therapy. [17] [18] [19] [20] Phase I studies with percutaneous delivery of TNFerade Biologic combined with adjunctive radiation therapy in a mixed population of patients with solid tumors, including 4 patients with pancreatic cancer, demonstrated objective responses. 8 Therefore, a dose-escalation study was performed to evaluate the dosing, feasibility, and tolerability of intratumoral injection of TNFerade Biologic with 5-FU and radiation therapy as first-line therapy for LAPC.
PATIENTS AND METHODS

Patient selection
Patients with histologically or cytologically confirmed adenocarcinoma of the exocrine pancreas that was not considered resectable for potential cure at the study site because of locally advanced disease involving major arteries (superior mesenteric artery, hepatic artery, aorta) or veins (portal vein, superior mesenteric vein) and without evidence of metastatic disease were eligible. No central radiology reading was performed at the time of enrollment. Additional criteria included Karnofsky performance status of Ͼ70%, life expectancy of Ͼ3 months, age 18 to 79 years, and measurable disease. Exclusion criteria included history of other malignancy in the past 2 years other than carcinoma in situ of the cervix or bladder, or early-stage localized prostate cancer; previous chemotherapy or radiation for pancreatic cancer or previous radiation to the target field; evidence of metastatic disease; history of pancreatitis or pancreatic pseudocyst; contraindication to EUS and percutaneously guided delivery; evidence of active infection; liver enzymes more than threefold of the upper limit of normal; evidence of coagulopathy (international normalized ratio Ͼ1.5 or partial thromboplastin time ratio Ͼ1.5); renal insufficiency (serum creatinine Ͼ2.0 mg/ dL), hematocrit Ͻ28% or hemoglobin Ͻ9 mg/dL, platelet count Ͻ100,000/L, leukocyte count Ͻ3000/L, absolute neutrophil count (ANC) Ͻ1500/L; pregnancy or lactation; longterm immunosuppressive medication; and investigational medications or other concurrent anticancer therapy within the 4 weeks before day 1 of the study. Written informed consent was required, and the protocol was reviewed and approved by each institution's institutional review board.
Treatment plan
The study was an open-label extended dose-escalation study designed to assess the safety, feasibility, and tolerability of intratumoral injection of TNFerade Biologic in patients undergoing first-line CRT for LAPC. The secondary and exploratory objectives included measuring the antitumor efficacy, comparing the different modes of delivery, and studying the effect of treatment on surgical downstaging.
Patients were injected immediately before radiation with TNFerade Biologic once a week for 5 weeks. Radiation and chemotherapy with 5-FU was started on day 1 and continued concomitantly with TNFerade Biologic for 5.5 weeks (Fig. 1) . Four dosage levels were evaluated: 4 ϫ 10 9 PU, 4 ϫ 10 10 PU, 4 ϫ 10 11 PU, and 1 ϫ 10 12 PU. Three to 6 patients were enrolled per dose depending on toxicity. In this phase I study of a novel agent in combination with CRT and an unusual means of delivery, additional patients were added to each cohort because of toxicities, technical issues, and Data Safety Monitoring Board requests. If no or only 1 dose-limiting toxicity (DLT) developed, dose escalation continued. A DLT was defined as any grade 3 or greater nonhematologic toxicity (except alopecia, nausea, vomiting and diarrhea, asymptomatic hyperamylasemia, or hyperlipasemia) or grade 4 hematologic toxicity (thrombocytopenia [platelets Ͻ10,000/ A total volume of 2 mL TNFerade Biologic-containing solution was injected via EUS or percutaneously on days 1, 8, 15, 24, and 32. The mode of delivery was left to the discretion of the individual study sites. In patients receiving endoscopic injection, after conscious sedation, the entire target tumors were visualized on EUS with a linear array echoendoscope, by using either a gastric or a duodenal approach, and were injected with 4 0.5-mL injections into different areas of the tumor with a protocol similar to that previously described by Hecht et al. 9 Percutaneous injections consisted of a single injection of 2.0 mL TNFerade Biologic into the tumor by using CT or ultrasound guidance.
External-beam radiation therapy was administered as 50. 
Safety and efficacy evaluations
Patients were monitored for adverse events, hematologic abnormalities including abnormal levels of lipase and amylase, changes evident on physical examination, plasma TNF-␣ levels, anti-TNF-␣ neutralizing antibody titers, viral genome shedding in urine and as shown by a throat swab, serial CA19-9 levels, and tumor size by CT scan. An external data safety monitoring board reviewed the patient safety data throughout the study.
Efficacy parameters were based on objective tumor response. Contrast medium-enhanced 3-mm slice helical CT scans were performed at baseline and 4 and 12 weeks after treatment. Objective tumor response was calculated based on the tumor area defined as the product of bidimensional measurements at each assessment. Tumor response was also determined by using Response Evaluation Criteria in Solid Tumors and World Health Organization criteria and was reviewed by a central radiology facility. 21 Other efficacy parameters included overall survival and progression-free survival.
RESULTS
Patient characteristics
A total of 50 patients were enrolled in this multicenter study. The characteristics of the entire cohort of patients are listed in Table 1 . The median age was 59 years (range, 35-79 years), and the median Karnofsky performance status was 90 (range, 70 -100). No patient had evidence of metastatic disease at the time of enrollment. Twenty-three patients were treated by percutaneous injection, and 27 patients received their injections by EUS-guided delivery.
Dose escalation
Ten patients received 4 ϫ 10 9 PU without treatment virusrelated DLTs. Twenty additional patients were treated at the 4 ϫ 10 10 PU dose with a single DLT resulting in a hypotensive episode. Eleven patients were subsequently treated with 4 ϫ 10 11 PU without any DLTs. However, at the 1 ϫ 10 12 PU dose, 9 patients were treated and 3 experienced associated DLTs (2 cases of pancreatitis and 1 of ascending cholangitis). All DLTs occurred after the administration of the first dose of TNFerade Biologic and resulted in termination of treatment in those 3 patients. Hence, the maximum tolerated dose (MTD) was set at 4 ϫ 10 11 PU.
Toxicity
In general the treatment was well tolerated. Overall grade 3 and 4 toxicities included GI bleeding, deep vein thrombosis (DVT), pulmonary emboli, pancreatitis, and cholangitis ( Table 2 ). Two of the 10 patients receiving the 4 ϫ 10 9 PU dose missed a prescribed dose because they had flulike symptoms and a prolonged partial thromboplastic time. One patient at this dose developed intestinal ischemia, which was thought by the investigator to be unrelated to the study drug. Of the 20 patients in the 4 ϫ 10 10 PU treatment group, 3 missed a prescribed TNFerade Biologic dose because they had pain, flulike symptoms, and progression in disease. Only 2 of the prescribed TNFerade Biologic doses were missed in 2 patients in the 4 ϫ 10 11 PU group because of patient preference and the diagnosis of a DVT. However, in the 1 ϫ 10 12 PU group, 2 cases of pancreatitis and a single case of cholangitis resulted in termination of treatment for those 3 patients, and an additional episode of hypokalemia and hypotension resulted in missed doses in another patient. Two patients died within 30 days of the end of treatment. One death was ascribed to progressive disease and the other to splenic artery thrombosis. Neither was thought by the investigators to be related to the treatment. Grade 3 and 4 toxicities are listed in Table 2 .
Efficacy
The results of the effect of treatment on the target tumor are summarized in Table 3 . A single complete response was seen in 1 patient (4 ϫ 10 10 PU cohort), and a partial response was seen in 3 patients (2 patients from the 4 ϫ 10 11 PU cohort and 2 from the 1 ϫ 10 12 PU cohort.) Twelve patients (24%) had stable disease, and 19 (38%) had progressive disease. The median time to tumor progression was 108 days (95% CI, 67-198 days) (Fig. 2) . Twenty patients (40%) were free from local progression at 3 months. Determining radiographic response in pancreatic tumors is made difficult by the desmoplastic nature of these tumors and surrounding chronic pancreatitis. 22 In other studies, reduction in serum levels of the tumor marker CA 19-9 have been correlated with outcome in pancreatic cancer patients undergoing treatment. [22] [23] [24] At the end of treatment, 15 of 46 patients had decreases of at least 50% from their baseline CA 19-9 level, which has been correlated with significantly better outcome. 24 The overall median survival was 297 days (95% CI, 201-316 days). However, the best median survival was seen in the 4 ϫ 10 11 PU cohort of 332 days (95% CI, 154-316 days) (Fig. 3) . On long-term follow-up of the 50 patients enrolled in this study, 1 was still alive 396 days after enrollment in the study. This patient was initially staged as having T4N1M0 disease, received 4 ϫ 1011 PU, underwent surgical resection after treatment, and was found to have a partial pathologic response. Further exploratory analysis studied the impact of mode of delivery on outcome. The method of TNFerade Biologic administration (either by EUS or by the percutaneous route) did not influence overall outcome (Fig. 4) .
A planned analysis (per protocol amendment) of the effect of treatment on tumor downstaging and eventual surgical resection was performed. All patients were initially thought to be unresectable. Seven patients underwent surgical resection some time after treatment, and 6 had negative surgical margins. One patient had a complete pathologic response.
DISCUSSION
We demonstrated the feasibility and safety of intratumoral gene therapy by either EUS-guided FNI or percutaneous Progressive disease 19 (38) Not applicable/nondiagnostic 8 (16) injection for the treatment of LAPC. Evidence of clinical efficacy was based on the tumor responses and surgical downstaging. The MTD of TNFerade Biologic was identified as 4 ϫ 10 11 PU in combination with standard 5-FU and radiotherapy for further study in a randomized clinical trial. This study has limitations, including the small size, the lack of standardization for criteria for locally advanced unresectability, and the nonrandomized study design.
Overall, the combination of chemotherapy, radiotherapy, and TNFerade Biologic was relatively well tolerated. Grade 3 or 4 nausea and vomiting was seen in 4 patients in this study, which is not uncommon with CRT alone. Gastrointestinal bleeding was seen in 6 patients in this study, although it is unclear whether it was related to treatment or to the underlying disease. Occluded biliary stents were the cause of nontreatment-related grade 3 and 4 nonhematologic toxicities in 8 patients, and cholangitis was observed in 6 patients. These toxicities quickly resolved after stent exchange. This result is comparable to a report showing stent occlusion in 15 of 100 patients undergoing CRT. 25 Grade 3 or 4 abdominal pain was seen in 9 patients and included 2 cases of pancreatitis (both of which were DLTs at the maximum dose) and a single case of acute cholecystitis. Although abdominal pain is a common symptom in patients with LAPC, severe pancreatitis is not. It is unclear from this study whether these cases represent the effect of the disease or the treatment.
Similarly, pancreatic cancer is also associated with an increased prothrombotic risk. Both chemotherapy treatment and pancreatic cancer are thought to be independent strong risk factors for the development of DVT. 26 In the current study, 6 patients developed DVTs, with 2 showing evidence of a pulmonary embolism, but no associated deaths. In a retrospective study of thrombotic events in patients with pancreatic adenocarcinoma, venous thrombosis was observed in 27%, and a pulmonary embolism occurred in 4% of patients, with 2% mortality. 27 In summary, the use of locally injected TNFerade Biologic with CRT did not appear to cause significant increased toxicity in this trial.
Responses to CRT are difficult to measure radiographically because of the surrounding pancreatitis and the pronounced desmoplastic reaction of this tumor. 22, 23 Nevertheless, 4 patients had a complete response (1 patient) or partial response (3 patients) based on CT radiology criteria. Although overall survival and progression-free survival were not primary endpoints of this dose escalation study, the results are comparable with those of larger phase III randomized studies in LAPC in which external-beam radiation and 5-FU chemotherapy were used for a similar patient profile based on age and functional status. 3, 28, 29 In those studies, the median progression-free survival ranged from 2.9 to 6.2 months and median survival from 8.2 to 11.4 months. This compares with the median progression-free survival of 3.6 months and overall survival in the current study of 9.8 months, with an overall survival in the MTD group (4 ϫ 10 11 PU) of 10.9 months. 3,29-32 The incidence of surgical resection in those patients initially deemed unresectable was examined in an unplanned exploratory analysis. Seven patients (14%) in this study subsequently underwent surgical resection, 6 with completely negative surgical margins and 1 with a complete pathologic response. This result hints at the local effect of TNFerade Biologic combined with CRT. Historical series of CRT for LAPC have reported secondary resectability rates in the range of 1% to 13% of patients. 33, [34] [35] [36] Predicting which patients may become resectable with treatment would be extremely helpful for future studies.
The role of CRT in the treatment of LAPC remains unclear. Although the combination of 5-FU and radiation historically has been a standard treatment, the trial by the Fédération Francophone de la Cancérologie Digestive and the Societe Francaise de Radiotherapie Oncologique of "intensive induction" with 5-FU, cisplatin, and high-dose radiotherapy followed by gemcitabine compared with gemcitabine alone brought the utility of this approach into question. 37 The gemcitabine arm alone had superior outcomes, although the CRT arm was clearly nonstandard, with excessive toxicity. More recently, however, Loehrer et al presented the results of the Eastern Cooperative Oncology Group 4201 trial, which randomized patients with LAPC to gemcitabine with radiotherapy or gemcitabine alone. 38 Although once again the trial used nonstandard CRT and also closed early because of poor accrual, there was a significant improvement in survival compared with chemotherapy alone. Until large randomized trials comparing standard CRT with gemcitabine-based chemotherapy alone, 5-FU and radiotherapy will be a reasonable basis for the addition of biologic agents and comparator arm.
In summary, this dose escalation study demonstrated the safety and feasibility of EUS-guided and percutaneously guided intratumoral TNFerade Biologic with standard CRT in the treatment of LAPC and identified a maximal tolerated dose. Encouraging activity has prompted the prospective randomized phase III Pancreatic Cancer Trial, which compares standard 5-FU plus radiotherapy with and without TNFerade Biologic. Recent reports have indicated that this trial was stopped for lack of efficacy. New molecular markers such as DPC4 or trial designs such as run-in chemotherapy may prospectively identify a subset of patients who have predominantly locoregional complications from their cancer and would benefit from a localized approach. 39 
